×
About 20,555 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  7,155 results

Pharmacological and pathological relevance of S100 proteins in neurological disorders.
https://doi.org/10.2174/1871527322666221128160653
CNS & Neurological Disorders Drug Targets; Goswami D, Anuradha U et. al.

Nov 30th, 2022 - The S100 protein is one of the calcium-binding proteins associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis. S100 proteins are expressed in central nervous system by oligodendrocytes, astrocytes and neurons duri...

Early onset hereditary neuronopathies: an update on non-5q motor neuron diseases.
https://doi.org/10.1093/brain/awac452
Brain : a Journal of Neurology; Zambon AA, Pini V et. al.

Nov 30th, 2022 - Hereditary motor neuropathies (HMN) were first defined as a group of neuromuscular disorders characterized by lower motor neuron dysfunction, slowly progressive length-dependent distal muscle weakness and atrophy, without sensory involvement. Thei...

Fasciculation electromechanical latency is prolonged in amyotrophic lateral sclerosis.
https://doi.org/10.1016/j.clinph.2022.11.005
Clinical Neurophysiology : Official Journal of the Intern... Planinc D, Muhamood N et. al.

Nov 29th, 2022 - In amyotrophic lateral sclerosis (ALS), motor neurons become hyperexcitable and spontaneously discharge electrical impulses causing fasciculations. These can be detected by two noninvasive methods: high-density surface electromyography (HDSEMG) an...

Role of Triggers on the Structural and Functional Facets of TDP-43.
https://doi.org/10.1016/j.neuroscience.2022.11.027
Neuroscience Camilus N, Quintero Arias C et. al.

Nov 29th, 2022 - Nuclear TDP-43 protein mitigates cellular function, but the dynamic nucleus-cytoplasm shuttling of TDP-43 is disrupted in diseases, such as Amyotrophic Lateral Sclerosis (ALS). The polymorphic nature of the TDP-43 structures in vitro and in vivo i...

Genetic and clinical characteristics of ALS patients with NEK1 gene variants.
https://doi.org/10.1016/j.neurobiolaging.2022.11.001
Neurobiology of Aging; Jiang Q, Lin J et. al.

Nov 29th, 2022 - NIMA-related kinase 1(NEK1) gene was related to amyotrophic lateral sclerosis (ALS). However, genetic spectrum and clinical characteristics of ALS patients with NEK1 variants was largely unknown. We conducted genetic analysis on 1587 Chinese ALS p...

see more →

Guidelines  3 results

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

ESPEN guideline clinical nutrition in neurology.
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  18 results see all →

Clinicaltrials.gov  539 results

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
https://clinicaltrials.gov/ct2/show/NCT05189106

Oct 14th, 2022 - Overview of Clinical Trial: Many age-associated neurodegenerative diseases, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS), are associated with increased inflammatory signaling in the central nervous system. While there...

Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
https://clinicaltrials.gov/ct2/show/NCT05178810

Oct 13th, 2022 - Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.

TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
https://clinicaltrials.gov/ct2/show/NCT04998305

Oct 13th, 2022 - In Japan, TJ-68 is a common Kampo medicine prescribed by Japanese physicians to manage muscle cramps or pain of diverse origins. In the USA, there are no effective medications to control muscle cramps and no approved medications to specifically tr...

A Study of BIIB067 When Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
https://clinicaltrials.gov/ct2/show/NCT04856982

Oct 13th, 2022 - The primary objective of this study is to evaluate the efficacy of BIIB067 when initiated in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to ...

A Study of Monepantel in Individuals With Motor Neurone Disease
https://clinicaltrials.gov/ct2/show/NCT04894240

Oct 12th, 2022 - Amyotrophic lateral sclerosis/ Motor Neurone Disease (ALS/MND) is a rare and invariably fatal neurological disease. ALS/MND has a terribly high burden on patients, family and carers, and carries great socioeconomic burden. Current best treatment o...

see more →

News  479 results

Trending Clinical Topic: Vitamin B12
https://www.medscape.com/viewarticle/983670

Nov 11th, 2022 - Each week, we identify one top search term, speculate about what caused its popularity, and provide an infographic on a related condition. If you have thoughts about what's trending and why, share them with us on Twitter or Facebook.  The potentia...

Amyotrophic Lateral Sclerosis (ALS)
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/336726

Learn about this progressive disease attacks the nerve cells that control voluntary movement.

Dementia Prediction and Blood Tests; Paraquat and Parkinson's; NIH Issues CTE Stance
https://www.medpagetoday.com/neurology/generalneurology/101415

Oct 25th, 2022 - Alzheimer's blood biomarkers indicated underlying pathology but added little to current 5-year dementia risk prediction models in people with subjective cognitive complaint or mild cognitive impairment. (Neurology) About one-third of patients spon...

Novel gene-based therapies for neuromuscular diseases
https://www.mdedge.com/neurology/article/258357/rare-diseases/novel-gene-based-therapies-neuromuscular-diseases
Nahomi Yewhalashet, Larry J. Davis, PharmD

Oct 15th, 2022 - Neuromuscular diseases (NMDs) are a broad classification of heterogeneous groups of disorders characterized by progressive muscle weakness resulting from muscle or nerve dysfunction. 1 Diagnosis is based on symptoms and a full medical history, as w.

Amylyx Prices Newly Approved ALS Drug at $158,000 Per Year
https://www.medscape.com/viewarticle/981708

Oct 3rd, 2022 - (Reuters) - Amylyx Pharmaceuticals Inc on Friday set the list price of its newly approved drug to treat amyotrophic lateral sclerosis (ALS) at about $158,000 per year in the United States, a discount to its most recently approved competitor. The d...

see more →

Patient Education  28 results see all →